FDA Approves New Treatment Option For Late-Stage Breast Cancer
 

The U.S. Food and Drug Administration approved Halaven (eribulin mesylate) to treat patients with metastatic breast cancer who have received at least two prior chemotherapy regimens for late-stage disease. Breast cancer is the second leading cause of cancer related death among women, according to the National Cancer Institute...

More...